PARIS, November 20, 2012 /PRNewswire/ --
Devices Projected
to Have up to Twice the Longevity of Comparable Products
Boston Scientific Corporation (NYSE: BSX) has received CE Mark
approval for increased longevity projections for the INCEPTA™,
ENERGEN™, PUNCTUA™, COGNIS® and TELIGEN® implantable cardioverter
defibrillators (ICDs) and cardiac resynchronization therapy
defibrillators (CRT-Ds). The longevity projections are based
on data submitted to the European authorities and vary for each
device dependent on the model type and settings.
Projected device longevity exceeds 10 years for some models of
Boston Scientific ICDs, approaches eight years for its CRT-D
devices, and is up to double that of comparable competitive device
models[1]. The company supports these devices with
warranties of up to 10 years*. Depending on the model, the
device warranties are also up to twice as long as other
currently-marketed comparable devices.
"We are pleased with the new labeling for our defibrillator
products which provides doctors and patients with additional
assurance about the longevity of these devices," said Michael Onuscheck, senior vice president and
president of Europe, Middle East and Africa at Boston Scientific. "Boston
Scientific ICDs and CRT-Ds benefit from our proprietary advanced
battery technology. The new battery was first introduced in the
COGNIS and TELIGEN devices in 2008 and has now been incorporated
into our newest devices. This European approval confirms the
confidence already expressed earlier this year by the United Stated
Food and Drug Administration."
"Device longevity is of primary importance for patients with
devices. As patients live longer, increased device longevity can
translate to fewer replacement procedures and a lower risk of
complications," said Vias Markides, consultant cardiologist and
chair of Arrhythmias, Royal Brompton
and Harefield NHS Foundation Trust, London. "Reducing re-intervention also has an
important impact on the health care economy, offering substantial
savings to service commissioners and offering operational
advantages for device implanting services. Boston Scientific ICDs
and CRT-D devices have shown a substantial increase in longevity
projections, which is backed up by an impressive warranty."
* Warranties: INCEPTA and ENERGEN VR
ICD: 10 years; INCEPTA and ENERGEN DR ICD: eight years; PUNCTUA and
TELIGEN ICD: seven years; INCEPTA and ENERGEN CRT-D: six years; and
PUNCTUA & COGNIS CRT-D: five years.
--------------------------------------------------
1. PUNCTUA™ ICD, ENERGEN™ ICD, INCEPTA™ ICD - PHYSICIAN'S
TECHNICAL MANUAL
Part Number: 358362-006, 5-22-12; TELIGEN® 100 - PHYSICIAN'S
TECHNICAL MANUAL
Part Number: 357449-010, 5-22-12; PUNCTUA™ CRT-D, ENERGEN™ CRT-D,
INCEPTA™ CRT-D - PHYSICIAN'S TECHNICAL MANUAL Part Number:
358373-007, 5-22-12; COGNIS® 100-D - PHYSICIAN'S TECHNICAL MANUAL
Part Number: 357483-012, 5-22-12
To view the Multimedia News Release including a video,
backgrounders and images, please click here:
http://www.epresspack.net/bsci
Visit the Boston Scientific Longevity Website here:
http://www.bostonscientific-international.com/ICDlongevity
For more news about Boston Scientific please follow us on
Twitter @bsc_eu_heart (https://twitter.com/BSC_EU_Heart).
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices that are used in a broad range of
interventional medical specialties. For more information, please
visit: http://www.bostonscientific.com.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements
are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be
guarantees of future events or performance. These forward-looking
statements include, among other things, statements regarding new
product launches and launch cadence, regulatory approvals, clinical
trials, product performance and competitive offerings. If our
underlying assumptions turn out to be incorrect, or if certain
risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some
cases, have affected and in the future (together with other
factors) could affect our ability to implement our business
strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All of
these factors are difficult or impossible to predict accurately and
many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties
that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K
filed with the Securities and Exchange Commission, which we may
update in Part II, Item 1A - Risk Factors in Quarterly
Reports on Form 10-Q we have filed or will file hereafter. We
disclaim any intention or obligation to publicly update or revise
any forward-looking statements to reflect any change in our
expectations or in events, conditions or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements. This cautionary statement is applicable
to all forward-looking statements contained in this document.